Last updated: October 4, 2026
APADAZ is an immediate-release Schedule II opioid combination containing benzhydrocodone hydrochloride and acetaminophen. Its excipient opportunity is primarily incremental: improving tablet manufacturability, disintegration, stability, swallowability, and supply-chain resilience without changing the approved immediate-release profile. The strongest commercial opportunities are generic or authorized-generic supply, excipient substitution under regulatory change control, contract manufacturing, and differentiated low-dose opioid presentations. APADAZ has no biosimilar pathway because it is a chemically synthesized small-molecule drug.
What is APADAZ and how does its formulation work?
APADAZ combines benzhydrocodone hydrochloride, a prodrug converted to hydrocodone, with acetaminophen. The product is supplied as an immediate-release tablet for short-term management of acute pain severe enough to require an opioid when alternative treatments are inadequate [1].
| Attribute |
APADAZ profile |
| Active ingredients |
Benzhydrocodone hydrochloride and acetaminophen |
| Strength |
6.12 mg benzhydrocodone hydrochloride and 325 mg acetaminophen per tablet |
| Dosage form |
Immediate-release tablet |
| FDA approval |
NDA 209341; approved June 2018 |
| Maximum labeled dose |
12 tablets per day |
| Maximum daily acetaminophen exposure |
3,900 mg |
| Controlled-substance status |
Schedule II |
| Primary sponsor |
KVK-Tech |
| Therapeutic category |
Acute pain opioid analgesic |
| Biosimilar relevance |
None; APADAZ is a small-molecule drug |
The active ingredient ratio creates a formulation constraint. Any change to tablet hardness, porosity, disintegration, dissolution, coating, or excipient level must preserve the release profile of both active ingredients. Acetaminophen is present at a clinically significant dose, so tablet size, blend uniformity, segregation control, and compression performance are important manufacturing variables.
What excipients are used in APADAZ tablets?
The APADAZ prescribing information identifies conventional oral-solid-dose excipients, including fillers, binders, disintegrants, lubricants, glidants, surfactants, and coating materials [1]. The product is not labeled as an abuse-deterrent formulation.
The public label identifies the following inactive ingredients:
| Excipient function |
APADAZ excipient |
| Diluent and compression aid |
Lactose monohydrate |
| Diluent and structural aid |
Microcrystalline cellulose |
| Binder |
Povidone |
| Disintegrant |
Croscarmellose sodium |
| Glidant |
Colloidal silicon dioxide |
| Lubricant |
Magnesium stearate |
| Surfactant or wetting aid |
Sodium lauryl sulfate |
| Processing or coating component |
Talc |
| Film-coating components |
Hypromellose, polyethylene glycol, titanium dioxide |
The exact commercial opportunity depends on the approved formulation and manufacturing process rather than on the presence of any single excipient. A supplier that replaces one excipient must address equivalence in tablet performance, dissolution, impurity control, stability, and processability.
Which excipient functions create the best commercial opportunities?
Direct-compression performance
The APADAZ formulation uses lactose monohydrate and microcrystalline cellulose to support tablet mass, compactibility, and dose uniformity. Suppliers can compete through:
- Co-processed lactose-cellulose systems
- Low-moisture grades for improved stability
- Direct-compression excipients with narrow particle-size distributions
- Higher-flow materials that reduce segregation
- Grades that improve tablet hardness at lower compression force
The commercial value is highest if the excipient reduces manufacturing costs or improves throughput without requiring a new clinical study.
Disintegration and dissolution
Croscarmellose sodium is a key performance excipient for an immediate-release tablet. The principal development objective is rapid and reproducible water uptake without excessive tablet gelling or variability.
Potential products include:
- Higher-efficiency superdisintegrants
- Co-processed disintegrant systems
- Excipients optimized for high-dose acetaminophen blends
- Materials that maintain dissolution after storage under elevated temperature and humidity
A replacement must be evaluated against both active ingredients. Benzhydrocodone and acetaminophen may not respond identically to changes in wettability, particle size, or tablet porosity.
Lubrication and ejection
Magnesium stearate supports tablet ejection but can reduce wettability or slow dissolution if overmixed. Commercial opportunities include:
- Lower-level magnesium stearate systems
- Alternative lubricants
- Shorter blending processes
- Lubricant systems that reduce dissolution sensitivity
- Formulations that improve tablet ejection at lower lubricant concentration
This area has practical value because over-lubrication is a common source of dissolution variability in immediate-release tablets.
Wetting and powder flow
Sodium lauryl sulfate and colloidal silicon dioxide can improve wetting and flow. Suppliers may offer alternatives with lower variability, lower dust generation, or improved compatibility with high-dose acetaminophen blends.
Any replacement for sodium lauryl sulfate must be assessed for taste, gastrointestinal tolerability, dissolution impact, and regulatory acceptability. Surfactant changes can materially alter the release of poorly wettable drug particles.
Film coating
The coating system supports tablet identification, swallowability, moisture protection, and handling. Commercial differentiation may come from:
- Low-weight coatings that preserve rapid disintegration
- Pigment systems with improved color consistency
- Moisture-barrier coatings
- Titanium-dioxide-free coating systems
- Coatings compatible with continuous tablet coating
- Improved printing or serialization performance
A coating modification is commercially attractive when it improves supply continuity or manufacturing efficiency without changing the tablet's dissolution profile.
What formulation patents protect APADAZ?
APADAZ patent protection must be assessed through the current FDA Orange Book and the relevant United States Patent and Trademark Office records. The Orange Book identifies patents listed for approved drug products and provides the reference point for Paragraph IV analysis [2].
The key patent categories are likely to include:
| Patent category |
Commercial significance |
| Benzhydrocodone composition patents |
May cover the active pharmaceutical ingredient or chemical form |
| Combination-product patents |
May cover benzhydrocodone with acetaminophen |
| Method-of-use patents |
May cover treatment of acute pain or dosing methods |
| Manufacturing patents |
May cover synthesis, purification, or tablet production |
| Formulation patents |
May cover excipient combinations, tablet properties, or release characteristics |
A formulation supplier should not assume that use of common excipients is unprotected. Patent risk can arise from a claimed combination of active ingredients, excipient ranges, tablet hardness, dissolution limits, particle-size distributions, or manufacturing steps.
The commercial assessment should separate:
- Freedom to operate for the generic formulation.
- Patentability of a modified excipient system.
- Bioequivalence risk.
- Regulatory burden for a formulation change.
- Ability to manufacture at commercial scale.
When does APADAZ lose exclusivity?
APADAZ exclusivity is controlled by a combination of FDA regulatory exclusivity and listed patent rights. FDA approval alone does not establish the complete generic-entry date.
For APADAZ, the relevant regulatory framework includes:
- Five-year new chemical entity exclusivity if applicable to the approved active moiety.
- Three-year exclusivity for certain applications containing new clinical investigations.
- Orange Book-listed patents.
- Paragraph IV certifications by abbreviated new drug application applicants.
- Thirty-month stays triggered by qualifying patent litigation.
- Controlled-substance manufacturing and distribution requirements.
APADAZ was approved in 2018, so any five-year NCE exclusivity period would have expired by 2023. Patent-based barriers may extend beyond regulatory exclusivity. The controlling expiration dates, pediatric adjustments, patent-term adjustments, and litigation effects must be taken from the current Orange Book and USPTO records rather than inferred from the approval date [2,3].
What is the Orange Book status of APADAZ?
The Orange Book is the authoritative FDA source for listed patents, exclusivity codes, therapeutic-equivalence information, and approved product details. APADAZ should be evaluated by reviewing:
- The active listing for NDA 209341.
- Patent numbers and expiration dates listed against the NDA.
- Whether any listed patents are method-of-use patents.
- Whether the Orange Book includes a delisting or expiration update.
- Whether an ANDA applicant has submitted a Paragraph IV certification.
- Whether litigation has triggered a 30-month stay.
A patent listed in the Orange Book does not automatically prevent all generic development. Its practical value depends on claim scope, validity, enforceability, claim construction, and whether a generic applicant can certify that its product does not infringe.
What Paragraph IV challenges and patent litigation affect APADAZ?
A Paragraph IV challenge would create potential litigation under the Hatch-Waxman Act. The principal litigation questions would be:
- Whether the challenged patent claims the active ingredient, combination, formulation, or method of use.
- Whether the ANDA product includes the claimed excipient system.
- Whether the generic applicant can carve out a patented method of use.
- Whether the patent survives validity and enforceability challenges.
- Whether a settlement permits a specific generic launch date.
Publicly available FDA and court records should be used to confirm the current status of any APADAZ Paragraph IV filing, infringement action, settlement, or authorized-generic arrangement. A commercial model should not treat an unverified Paragraph IV filing as evidence of imminent market entry.
What generic entry risks exist for APADAZ?
The largest entry risk is a standard immediate-release hydrocodone-acetaminophen generic that demonstrates bioequivalence while avoiding valid formulation claims. Common excipients provide limited differentiation unless the innovator owns enforceable claims directed to a particular combination or process.
| Generic-entry scenario |
Likely commercial effect |
| No approved ANDA |
Continued branded or authorized-generic control |
| ANDA with non-infringement certification |
Potential entry after regulatory clearance and patent resolution |
| Paragraph IV litigation |
Delayed entry, legal-cost exposure, possible settlement |
| Formulation patent invalidated |
Higher probability of competitive launch |
| Authorized generic launch |
Lower price pressure than multiple independent generics |
| Multiple approved generics |
Significant erosion in price and market share |
APADAZ also faces substitution pressure from established hydrocodone-acetaminophen products, including generic tablets containing hydrocodone bitartrate and acetaminophen. Physicians and pharmacies may treat APADAZ as a clinically differentiated product only if its prodrug profile, supply, contracting position, or prescriber adoption creates a meaningful advantage.
How strong is the APADAZ patent estate?
Patent strength depends on claim breadth, remaining term, prosecution history, validity, and the availability of non-infringing formulations. A composition claim covering benzhydrocodone itself may be stronger against generic substitution than a narrow excipient claim. A method-of-use claim may be vulnerable to a label carve-out. A formulation claim limited to conventional excipient ranges may be easier to design around.
From an excipient perspective, the strongest defensible position would generally involve a specific technical relationship, such as:
- A defined dissolution profile linked to excipient ratios.
- A stability advantage tied to moisture control.
- A manufacturing process that produces consistent content uniformity.
- A tablet architecture that improves performance without extended release.
- A coating system that preserves immediate release under defined conditions.
A patent directed only to the use of a routine excipient at a conventional level may provide limited exclusionary value.
What licensing and partnership opportunities exist?
The most credible commercial opportunities are formulation and supply partnerships rather than broad licensing of APADAZ technology.
Potential counterparties include:
- Generic pharmaceutical companies seeking an opioid-acetaminophen product.
- Excipient manufacturers with direct-compression platforms.
- Contract development and manufacturing organizations.
- Specialty distributors with controlled-substance infrastructure.
- Companies developing abuse-risk mitigation or tamper-evident packaging.
- Regional licensees for markets outside the United States.
A licensing deal would need to address controlled-substance quotas, DEA registration, pharmacovigilance, product liability, diversion controls, minimum purchase commitments, and territory-specific regulatory approvals. Publicly verified licensing terms for APADAZ should not be assumed without a disclosed agreement or regulatory filing.
How does APADAZ compare with conventional hydrocodone-acetaminophen tablets?
| Factor |
APADAZ |
Conventional hydrocodone-acetaminophen generic |
| Opioid component |
Benzhydrocodone, converted to hydrocodone |
Hydrocodone salt |
| Acetaminophen |
325 mg per tablet |
Commonly 300 mg or 325 mg |
| Dosage form |
Immediate-release tablet |
Immediate-release tablet |
| Regulatory pathway |
NDA |
ANDA for generic products |
| Biosimilar risk |
None |
None |
| Excipient differentiation |
Possible but limited |
Usually low |
| Controlled-substance controls |
High |
High |
| Main commercial differentiator |
Product identity, supply, formulation, and contracting |
Price and availability |
APADAZ competes in a mature opioid combination market. The main constraint is not excipient availability. It is the limited clinical and commercial differentiation of another immediate-release opioid-acetaminophen tablet.
Key Takeaways
- APADAZ is an immediate-release benzhydrocodone hydrochloride/acetaminophen tablet approved under NDA 209341.
- Its excipient system uses conventional oral-solid-dose materials, including lactose, microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and film-coating components.
- The best excipient opportunities involve improved flow, compression, disintegration, dissolution consistency, moisture protection, and supply resilience.
- APADAZ has no biosimilar pathway because it is a small-molecule drug.
- Generic-entry risk depends on current Orange Book patents, Paragraph IV certifications, litigation, settlements, and FDA approval status.
- A formulation change can create regulatory and patent risk even when each individual excipient is conventional.
- The strongest commercial opportunities are generic development, authorized-generic supply, contract manufacturing, excipient substitution, and regional licensing.
- APADAZ competes against established hydrocodone-acetaminophen generics, limiting the pricing power of formulation differentiation.
FAQs About APADAZ Excipients, Patents, and Market Entry
Is APADAZ an abuse-deterrent opioid?
No. APADAZ is an immediate-release opioid combination. Its FDA labeling does not establish an abuse-deterrent formulation claim.
Can a generic manufacturer use different excipients from APADAZ?
Yes, if the product satisfies applicable FDA requirements, demonstrates bioequivalence, and does not infringe enforceable patent claims. Different excipients may alter dissolution, stability, or manufacturability.
Does APADAZ have biosimilar competition?
No. Biosimilar rules apply to biological products. APADAZ is a chemically synthesized small-molecule drug and would be challenged through the ANDA pathway.
Can a coating change create a new APADAZ product opportunity?
Yes. A coating change may improve moisture protection, swallowability, appearance, or manufacturing efficiency. It must preserve immediate release and satisfy regulatory requirements.
What is the main commercial barrier to an APADAZ generic?
The main barriers are active patent rights, Paragraph IV litigation, controlled-substance compliance, bioequivalence requirements, and competition from established hydrocodone-acetaminophen products.
References
- U.S. Food and Drug Administration. (2018). APADAZ (benzhydrocodone hydrochloride and acetaminophen) tablets, prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications.
- U.S. Drug Enforcement Administration. (n.d.). Controlled substances schedules.
